|
Revenue from operations rose marginally to Rs 344.03 crore in the June quarter as against Rs 338.80 crore reported in Q1 FY23.
Profit before tax grew by 9.1% year on year to Rs 153.66 crore in the quarter ended 30 June 2023.
EBITDA for the quarter was at Rs 179.94 crore, up 8.63% as against Rs 165.64 crore reported in Q1 FY23. EBITDA margin improved to 50.82% in Q1 FY24 as compared to 47.37% recorded in the corresponding quarter previous year.
On consolidated basis, the company's net profit rose 12.1% to Rs 120.59 crore on 2.6% increase in revenue to Rs 347.55 crore in Q1 FY24 over Q1 FY23.
Suven Pharmaceuticals is in the business of Contract Development & Manufacturing Organisation (CDMO), catering to the needs of global pharma industry.
Shares of Suven Pharmaceuticals gained 0.72% to Rs 492.50 on the BSE.
|